CL2024000370A1 - Composiciones y métodos para el tratamiento de cáncer. - Google Patents

Composiciones y métodos para el tratamiento de cáncer.

Info

Publication number
CL2024000370A1
CL2024000370A1 CL2024000370A CL2024000370A CL2024000370A1 CL 2024000370 A1 CL2024000370 A1 CL 2024000370A1 CL 2024000370 A CL2024000370 A CL 2024000370A CL 2024000370 A CL2024000370 A CL 2024000370A CL 2024000370 A1 CL2024000370 A1 CL 2024000370A1
Authority
CL
Chile
Prior art keywords
compositions
treatment
cancer
methods
beta
Prior art date
Application number
CL2024000370A
Other languages
English (en)
Spanish (es)
Inventor
Chatterjee Subroto
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of CL2024000370A1 publication Critical patent/CL2024000370A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)
    • G01N2333/91102—Hexosyltransferases (general) (2.4.1) with definite EC number (2.4.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2024000370A 2021-08-10 2024-02-06 Composiciones y métodos para el tratamiento de cáncer. CL2024000370A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163231694P 2021-08-10 2021-08-10

Publications (1)

Publication Number Publication Date
CL2024000370A1 true CL2024000370A1 (es) 2024-10-25

Family

ID=85201061

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000370A CL2024000370A1 (es) 2021-08-10 2024-02-06 Composiciones y métodos para el tratamiento de cáncer.

Country Status (9)

Country Link
US (1) US20240360247A1 (cg-RX-API-DMAC10.html)
EP (1) EP4384220A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024533998A (cg-RX-API-DMAC10.html)
CN (1) CN118139642A (cg-RX-API-DMAC10.html)
AU (1) AU2022326557A1 (cg-RX-API-DMAC10.html)
CA (1) CA3225489A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000370A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024001405A2 (cg-RX-API-DMAC10.html)
WO (1) WO2023019186A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025171394A1 (en) * 2024-02-09 2025-08-14 The Johns Hopkins University Compositions and methods for treatment of cancer
CN119861198B (zh) * 2025-01-02 2025-09-16 哈尔滨脉图精准技术有限公司 用于区分早期肺癌与肺炎的血浆代谢标志物组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005277186A1 (en) * 2004-08-20 2006-03-02 The Johns Hopkins University Methods for treatment of angiogenesis
US11339213B2 (en) * 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
PT3370768T (pt) * 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
WO2019033050A1 (en) * 2017-08-11 2019-02-14 City Of Hope BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN
EP3801471A4 (en) * 2018-06-05 2022-04-06 Chatterjee, Subroto B. INHIBITORS OF GLYCOSPHINGOLIPID SYNTHESIS AND METHODS OF USE

Also Published As

Publication number Publication date
CO2024001405A2 (es) 2024-07-29
US20240360247A1 (en) 2024-10-31
CA3225489A1 (en) 2023-02-16
AU2022326557A1 (en) 2024-01-25
JP2024533998A (ja) 2024-09-18
EP4384220A4 (en) 2025-06-18
WO2023019186A2 (en) 2023-02-16
CN118139642A (zh) 2024-06-04
EP4384220A2 (en) 2024-06-19
WO2023019186A3 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
MX2023012245A (es) Compuestos, composiciones y metodos para el tratamiento del cancer.
SA520411108B1 (ar) مركبات حلقية كبيرة واستخداماتها
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2024012801A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
MX389683B (es) Composiciones terapeuticas, combinaciones y metodos de uso
PH12017502002A1 (en) 5`-substituted nucleoside analogs
CO2024001405A2 (es) Composiciones y métodos para el tratamiento de cáncer
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
CR20240296A (es) Inhibidores parp1
MX374946B (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil)]-fosfato) para usarse en el tratamiento de cáncer para hacer blanco en las células de cáncer.
CL2024001535A1 (es) Quinolinas y azaquinolinas como inhibidores de cd38
BR112022023254A2 (pt) Monoterapias e terapias de combinação
MX2022007626A (es) Combinaciones.
MX2025002424A (es) Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer
MX2016016507A (es) Composiciones y metodos para tratar canceres.
MX2022007628A (es) Combinaciones.
MX2018011046A (es) Composiciones y metodos para tratar canceres.
MX387726B (es) Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer.
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
PH12017501881A1 (en) Methods for treating cancer
MX2022014461A (es) Nuevos abridores de canales de potasio maxi-k para el tratamiento de trastornos asociados con x fragil.